ArticleScientific reports2019
Risk Factors of Neovascular Glaucoma After 25-gauge Vitrectomy for Proliferative Diabetic Retinopathy with Vitreous Hemorrhage: A Retrospective Multicenter Study.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- The role of artificial intelligence in analysis of biofluid markers for diagnosis and management of glaucoma: A systematic review.European journal of ophthalmology · 2023Pooled it
- Preoperative anti-VEGF and the cumulative risk of post-operative vitreous hemorrhage in PDR: a 2-year survival analysis and evaluation of surgical burden.International journal of retina and vitreous · 2026Article
- Development and Novel Therapeutics in Diabetic Retinopathy.Current diabetes reviews · 2026Review
- Association between stress hyperglycemia ratio and diabetic retinopathy progression and surgical prognosis: insights from NHANES 2005-2018 and clinical cohort study.Diabetology & metabolic syndrome · 2025Article
- Natural remedies proposed for the management of diabetic retinopathy (DR): diabetic complications.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Causes and prognosis of neovascular glaucoma after pars plana vitrectomy in patients with diabetic retinopathy.BMC ophthalmology · 2025Article
- A risk prediction model for neovascular glaucoma secondary to proliferative diabetic retinopathy based on Boruta feature selection and random forest.Frontiers in cell and developmental biology · 2025Article
- Integrative Management of High-Risk Proliferative Diabetic Retinopathy: Precision Diagnostics via Ultra-Widefield Imaging and Therapeutic Strategies.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Bilateral vitrectomy in patients with proliferative diabetic retinopathy-characteristics and surgical outcomes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- Factors Affecting the Results of Ahmed Glaucoma Valve Implantation in Diabetic Neovascular Glaucoma With or Without Previous Pars Plana Vitrectomy.Beyoglu eye journal · 2024Article
- A prediction model for worsening diabetic retinopathy after panretinal photocoagulation.Diabetology & metabolic syndrome · 2022Article
- Inner limiting membrane peeling prevents secondary epiretinal membrane after vitrectomy for proliferative diabetic retinopathy.International journal of ophthalmology · 2022Article
- Ocular findings, surgery details and outcomes in proliferative diabetic retinopathy patients with chronic kidney disease.PloS one · 2022Article
- Prognostic Evaluation of Vitrectomy Assisted by Lucentis in Diabetic Retinopathy and Neovascular Glaucoma.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Clinical Manifestations of Supra-Large Range Nonperfusion Area in Diabetic Retinopathy.International journal of clinical practice · 2022Article
- Is Chronic Kidney Disease Affecting the Postoperative Complications of Vitrectomy for Proliferative Diabetic Retinopathy?Journal of clinical medicine · 2021Article
- Potential bias of preoperative intravitreal anti-VEGF injection for complications of proliferative diabetic retinopathy.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neovascular glaucoma (NVG) is a terminal severe complication in eyes with proliferative diabetic retinopathy (PDR), and PDR eyes with vitreous hemorrhage (VH) which undergo vitrectomy may have higher risk of postoperative NVG. The incidence and the prognostic factor of postoperative NVG after 25-gauge vitrectomy with advanced surgical options remain unclear. We retrospectively reviewed medical records of 268 eyes of 268 consecutive PDR patients with VH who underwent 25-gauge vitrectomy and 12 months follow-up at seven centers. Preoperative ocular factors (visual acuity, tractional retinal detachment, panretinal photocoagulation [PRP]), demographics and clinical factors (sex, age, diabetic duration, HbA1c, hypertension, anticoagulant medication, and kidney function), surgical procedures, and postoperative complications were compared between patients who developed postoperative NVG (9.3%) and those who did not. NVG eyes was significantly younger (P = 0.026), had shorter diabetic duration (P = 0.022), higher HbA1c (P = 0.028), absence of PRP (P = 0.039) and higher frequency of postoperative VH (P = 0.0075) than non-NVG eyes. Logistic regression analysis identified postoperative VH (P = 0.014), shorter diabetic duration (P = 0.029), and no PRP (P = 0.028) as prognostic factors for postoperative NVG. This multicenter study indicates that younger age, uncontrolled diabetes, no PRP, and postoperative VH are risk factors of post-vitrectomy NVG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.